Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reiterated by stock analysts at FinnCap in a research note issued to investors on Thursday. They presently have a GBX 46 ($0.60) price objective on the stock. FinnCap’s target price suggests a potential upside of 60.00% from the company’s current price.

Separately, Numis Securities Ltd reiterated a “buy” rating and set a GBX 45 ($0.58) target price on shares of Allergy Therapeutics plc in a report on Tuesday, July 18th.

Allergy Therapeutics plc (LON:AGY) opened at 28.75 on Thursday. Allergy Therapeutics plc has a one year low of GBX 17.25 and a one year high of GBX 31.00. The firm’s 50-day moving average is GBX 28.82 and its 200 day moving average is GBX 27.15. The company’s market capitalization is GBX 170.61 million.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/26/allergy-therapeutics-plc-agy-rating-reiterated-by-finncap.html.

About Allergy Therapeutics plc

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.